INFLAMMATORY BOWEL DISEASE MARKET ANALYSIS

Key Developments

• In May 2024, Johnson & Johnson Services announced positive phase 3 results for Tremfya in its Crohn’s disease program, demonstrating superiority over Stelara in all endoscopic patients in the trial.
• In April 2024, Takeda Pharmaceutical Company Limited received FDA approval for the subcutaneous administration of Entyvio following induction therapy with intravenous Entyvio, for treating patients with severely active Crohn’s Disease.
• In October 2023, Johnson & Johnson Services Inc. reported phase 3 trial data for Tremfya in active ulcerative colitis, showing a 77% overall clinical response rate and early symptom improvement.
• In June 2023, Lilly's Omvoh (mirikizumab) received market authorization from the UK's MHRA for treating ulcerative colitis.
• In February 2023, AbbVie announced that the UK's MHRA approved RINVOQ, a JAK inhibitor, for moderate to severe Crohn's disease in patients who did not respond adequately to conventional therapy.
• In January 2023, Inotrem, a clinical-stage biotechnology company, received funding from the Crohn's & Colitis Foundation to support the development of innovative therapeutic approaches for Crohn's disease and ulcerative colitis.